20% of those in the High Dose Group, and 6% of those in the low dose group in Moderna’s preliminary Covid Vaccine trials experienced Grade 3 adverse events (Severe/Medically significant Adverse Event)
https://www.fiercebiotech.com/biotech/moderna-posts-positive-early-data-for-covid-19-vaccine